Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dendritic cell-activated cytotoxic T lymphocytes cells - Shenzhen Hornetcorn Biotechnology

Next Previous
Drug Profile

Dendritic cell-activated cytotoxic T lymphocytes cells - Shenzhen Hornetcorn Biotechnology

Alternative Names: DC activated CTL - Shenzhen Hornetcorn Biotechnology; DC-CTL - Shenzhen Hornetcorn Biotechnology; Dendritic cell cytotoxic T lymphocyte cell therapy - Shenzhen Hornetcorn Biotechnology

Latest Information Update: 28 Jun 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shenzhen Hornetcorn Biotechnology
  • Class Antineoplastics; Cell therapies; Dendritic cell vaccines; Immunotherapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Non-small cell lung cancer

Most Recent Events

  • 28 Jun 2019 No recent reports of development identified for clinical-Phase-Unknown development in Non-small-cell-lung-cancer in China (IV, Infusion)
  • 06 May 2016 Shenzhen Hornetcorn Bio-technology Company plans a phase II trial for Non-small cell lung cancer (Late-stage disease, Combination therapy) in China (IV) (NCT02766348)
  • 05 May 2016 Clinical trials in Non-small cell lung cancer in China (IV) before May 2016
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top